We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current SRNAF market cap is 0. The company's latest EPS is USD and P/E is N/A.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 343k | 691k | 137k | 761k | 455k |
| Operating Income | -14.54M | -29.19M | -69.53M | -91.52M | -85.6M |
| Net Income | -16.38M | -43.77M | -213.07M | -88.3M | -78.69M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 24.82M | 110.18M | 240.65M | 163.93M | 75.79M |
| Total Liabilities | 73.78M | 204.36M | 30.36M | 52.37M | 51.33M |
| Total Equity | -48.95M | -94.18M | 210.29M | 111.56M | 24.46M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -14.4M | -19M | -56.97M | -88.71M | -70.29M |
| Investing | 1.1M | 8.39M | -6.04M | -32.61M | -5.35M |
| Financing | 11.55M | 100.37M | 170.96M | 15.89M | -5.61M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 87.64M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Sirnaomics Ltd (PK) |
| Address |
po box 309 grand cayman KY1-1104 |
| Website | https://www.sirnaomics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
